# The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

> **NCT06950645** · PHASE1 · COMPLETED · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Rotavirus Gastroenteritis

## Interventions

- **BIOLOGICAL:** Oral hexavalent reassortant rotavirus attenuated live vaccine
- **BIOLOGICAL:** Oral hexavalent reassortant rotavirus attenuated live vaccine
- **BIOLOGICAL:** Oral hexavalent reassortant rotavirus attenuated live vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Oral hexavalent reassortant rotavirus attenuated live vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06950645
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-27
- **Primary completion:** 2024-12-21
- **Final completion:** 2025-12-18
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06950645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06950645, "The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06950645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*